| Autor: |
Parnham, Michael J., Bruinvels, J., Furr, Barrington J. A., Howell, Anthony, Wakeling, Alan |
| Zdroj: |
Aromatase Inhibitors (978-3-7643-8692-4); 2008, p101-125, 25p |
| Abstrakt: |
Oestrogens play a dominant role in controlling the growth of many breast cancers [1, 2]. The ovaries are the primary source of oestrogen in premenopausal women but ovarian oestrogen production diminishes with age. In postmenopausal women, oestrogens are synthesised by the aromatisation of androgen precursors in the skin, muscle, adipose and breast tissue, including malignant breast tumours [3]. Oestrogen action is inhibited by blocking the oestrogen receptor (ER) with antioestrogens such as tamoxifen, by ovarian ablation using surgery, radiotherapy or luteinising hormone-releasing hormone analogs such as goserelin, or, in postmenopausal women, by blocking oestrogen production by inhibiting aromatase activity [4]. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
